StockData
ELI LILLY & Co logo

ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

Eli Lilly strattera (atomoxetine) — Outside U.S. revenue ($M) [legacy] ($M)

Quarterly figures from Eli Lilly's filings and investor materials

Latest, Q4 2019
42.3
Period ended Dec 31, 2019
Change on a year earlier
-54.0%
91.9 in Q4 2018
History
12 quarters
Since Q1 2017
Sources
7
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedStrattera (atomoxetine) — Outside U.S. revenue ($M) [legacy] ($M)Year on yearSource
Q4 2019Dec 31, 201942.3-54.0%Form 10-K (filed 2020-02-19) ↗
Q3 2019Sep 30, 201943.3-50.9%Form 10-Q (filed 2019-10-25) ↗
Q2 2019Jun 30, 201961.4-36.9%Form 10-Q (filed 2019-08-02) ↗
Q1 2019Mar 31, 201964.7-22.7%Form 10-Q (filed 2019-05-02) ↗
Q4 2018Dec 31, 201891.9+1.8%Form 10-K (filed 2020-02-19) ↗
Q3 2018Sep 30, 201888.2+4.9%Form 10-Q (filed 2019-10-25) ↗
Q2 2018Jun 30, 201897.3+14.3%Form 10-Q (filed 2019-08-02) ↗
Q1 2018Mar 31, 201883.7+13.4%Form 10-Q (filed 2019-05-02) ↗
Q4 2017Dec 31, 201790.3–Form 10-K (filed 2020-02-19) ↗
Q3 2017Sep 30, 201784.1–Form 10-Q (filed 2018-11-06) ↗
Q2 2017Jun 30, 201785.1–Form 10-Q (filed 2018-07-25) ↗
Q1 2017Mar 31, 201773.8–Form 10-Q (filed 2018-04-27) ↗

Cite this data

StockData. (2026). Eli Lilly Strattera (atomoxetine) — Outside U.S. revenue ($M) [legacy] ($M), quarterly Q1 2017–Q4 2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_strattera_nonus

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.